title: Progress in respiratory virus vaccine development.
abstract: Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 10001, USA. schmidta@niaid.nih.gov
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Schmidt
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D015195:Drug Design; D006801:Humans; D007223:Infant; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014765:Viral Vaccines / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology
chemical_list: D014765:Viral Vaccines